Mochida Pharmaceutical Co., Ltd. (4534.T)
JPY 3090.0
(0.16%)
JPY 3090.0
(0.16%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.97 Billion JPY | -25.72% |
| 2022 | 11.71 Billion JPY | -32.93% |
| 2021 | 17.28 Billion JPY | 14.44% |
| 2020 | 14.74 Billion JPY | 4.74% |
| 2019 | 11.53 Billion JPY | 4.15% |
| 2018 | 14.55 Billion JPY | -5.35% |
| 2017 | 14.73 Billion JPY | 1.65% |
| 2016 | 14.32 Billion JPY | -5.13% |
| 2015 | 14.87 Billion JPY | 1.56% |
| 2014 | 14.16 Billion JPY | -23.67% |
| 2013 | 18.57 Billion JPY | 14.53% |
| 2012 | 16.95 Billion JPY | -6.58% |
| 2011 | 18.12 Billion JPY | 22.57% |
| 2010 | 11.06 Billion JPY | -16.1% |
| 2009 | 18.64 Billion JPY | 9.31% |
| 2008 | 16.43 Billion JPY | 1.14% |
| 2007 | 17 Billion JPY | 20.08% |
| 2006 | 13.43 Billion JPY | 6.91% |
| 2005 | 12.36 Billion JPY | 39.88% |
| 2004 | 7.59 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 173 Million JPY | -80.07% |
| 2024 Q2 | 2.41 Billion JPY | 1297.69% |
| 2023 FY | - JPY | -25.72% |
| 2023 Q4 | 761 Million JPY | -62.04% |
| 2023 Q3 | 2 Billion JPY | 37.14% |
| 2023 Q1 | 2.59 Billion JPY | 276.57% |
| 2023 Q2 | 1.46 Billion JPY | -43.6% |
| 2022 Q1 | 4.26 Billion JPY | 128.99% |
| 2022 Q4 | -1.46 Billion JPY | -128.91% |
| 2022 Q3 | 5.07 Billion JPY | 385.93% |
| 2022 Q2 | 1.04 Billion JPY | -75.5% |
| 2022 FY | - JPY | -32.93% |
| 2021 Q4 | 1.86 Billion JPY | -73.45% |
| 2021 Q1 | 2.73 Billion JPY | 169.53% |
| 2021 FY | - JPY | 14.44% |
| 2021 Q2 | 2.98 Billion JPY | 9.15% |
| 2021 Q3 | 7.01 Billion JPY | 135.27% |
| 2020 Q2 | 2.69 Billion JPY | -41.02% |
| 2020 FY | - JPY | 4.74% |
| 2020 Q1 | 4.56 Billion JPY | 38.26% |
| 2020 Q4 | 1.01 Billion JPY | -75.19% |
| 2020 Q3 | 4.08 Billion JPY | 51.71% |
| 2019 Q2 | 1.71 Billion JPY | -62.09% |
| 2019 Q1 | 4.51 Billion JPY | 791.58% |
| 2019 FY | - JPY | 4.15% |
| 2019 Q4 | 3.3 Billion JPY | 53.1% |
| 2019 Q3 | 2.15 Billion JPY | 26.05% |
| 2018 FY | - JPY | -5.35% |
| 2018 Q2 | 1.47 Billion JPY | -76.61% |
| 2018 Q3 | 3.82 Billion JPY | 160.34% |
| 2018 Q4 | -653 Million JPY | -117.06% |
| 2018 Q1 | 6.28 Billion JPY | 1385.48% |
| 2017 Q4 | -489 Million JPY | -111.55% |
| 2017 Q3 | 4.23 Billion JPY | 95.02% |
| 2017 Q1 | 6.09 Billion JPY | 463.19% |
| 2017 FY | - JPY | 1.65% |
| 2017 Q2 | 2.17 Billion JPY | -64.41% |
| 2016 Q2 | 3.14 Billion JPY | -27.27% |
| 2016 Q4 | -1.67 Billion JPY | -128.58% |
| 2016 Q3 | 5.87 Billion JPY | 86.95% |
| 2016 FY | - JPY | -5.13% |
| 2016 Q1 | 4.32 Billion JPY | 1778.26% |
| 2015 FY | - JPY | 1.56% |
| 2015 Q4 | 230 Million JPY | -95.37% |
| 2015 Q3 | 4.96 Billion JPY | 78.38% |
| 2015 Q2 | 2.78 Billion JPY | -37.02% |
| 2015 Q1 | 4.42 Billion JPY | 63.35% |
| 2014 Q2 | 1.79 Billion JPY | -30.31% |
| 2014 Q3 | 4.86 Billion JPY | 171.47% |
| 2014 Q4 | 2.7 Billion JPY | -44.32% |
| 2014 FY | - JPY | -23.67% |
| 2014 Q1 | 2.57 Billion JPY | -8.08% |
| 2013 Q1 | 4.19 Billion JPY | 67.84% |
| 2013 Q3 | 5.97 Billion JPY | 54.72% |
| 2013 Q4 | 2.79 Billion JPY | -53.22% |
| 2013 FY | - JPY | 14.53% |
| 2013 Q2 | 3.86 Billion JPY | -7.83% |
| 2012 FY | - JPY | -6.58% |
| 2012 Q3 | 3.54 Billion JPY | -13.95% |
| 2012 Q4 | 2.49 Billion JPY | -29.46% |
| 2012 Q1 | 4.07 Billion JPY | 185.89% |
| 2012 Q2 | 4.11 Billion JPY | 0.98% |
| 2011 Q1 | 1.24 Billion JPY | -7.44% |
| 2011 Q2 | 6.32 Billion JPY | 408.2% |
| 2011 Q4 | 1.42 Billion JPY | -77.62% |
| 2011 FY | - JPY | 22.57% |
| 2011 Q3 | 6.36 Billion JPY | 0.7% |
| 2010 Q2 | 3.86 Billion JPY | -12.24% |
| 2010 Q1 | 4.4 Billion JPY | 60.95% |
| 2010 Q3 | 5.31 Billion JPY | 37.56% |
| 2010 Q4 | 1.34 Billion JPY | -74.71% |
| 2010 FY | - JPY | -16.1% |
| 2009 Q2 | 4.81 Billion JPY | -2.49% |
| 2009 Q4 | 2.73 Billion JPY | -48.43% |
| 2009 Q3 | 5.3 Billion JPY | 10.23% |
| 2009 Q1 | 4.93 Billion JPY | 96.34% |
| 2009 FY | - JPY | 9.31% |
| 2008 Q4 | 2.51 Billion JPY | -54.08% |
| 2008 Q2 | 3.2 Billion JPY | 0.0% |
| 2008 FY | - JPY | 1.14% |
| 2008 Q3 | 5.47 Billion JPY | 70.66% |
| 2007 FY | - JPY | 20.08% |
| 2006 FY | - JPY | 6.91% |
| 2005 FY | - JPY | 39.88% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -49.028% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 98.974% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 103.192% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 95.194% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -1471.531% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 75.274% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 26.853% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 91.297% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -593.968% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 51.074% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -144.496% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -539.558% |
| Tsumura & Co. | 30.77 Billion JPY | 70.84% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 52.067% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -70.233% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 74.75% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | -30.384% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 48.789% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 12.85% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 339.28% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | -18.8% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 1356.723% |
| MedRx Co., Ltd | -884.51 Million JPY | 1114.453% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -62.076% |
| Solasia Pharma K.K. | -635 Million JPY | 1513.071% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 477.982% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 2.074% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 75.665% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1766.948% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 65.281% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -75.885% |